Hims & Hers Health (NYSE:HIMS) Insider Soleil Boughton Sells 3,461 Shares of Stock

Key Points

• Insider selling: Soleil Boughton sold 3,461 Hims & Hers shares for about $101,000 under a pre-arranged Rule 10b5-1 plan, reducing the position by 1.14% while retaining 300,809 shares.
• Mixed financial performance: Hims & Hers reported quarterly revenue of $753.2 million, up 38.2% year over year and above estimates, but missed EPS expectations and posted negative net margin and return on equity.
• Investor outlook remains cautious: Shares traded near $28.96, while analysts maintained a consensus “Hold” rating with an average price target of $32.43. FTC-related controversy and securities litigation continue to weigh on sentiment and could increase volatility.

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) insider Soleil Boughton sold 3,461 shares of Hims & Hers Health stock in a transaction on Wednesday, September 30th. The shares were sold at an average price of $29.17, for a total transaction of $100,957.37. Following the completion of the sale, the insider directly owned 300,809 shares of the company's stock, valued at approximately $8,774,598.53. The trade was a 1.14% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Soleil Boughton also recently made the following trade(s):

• On Wednesday, September 16th, Soleil Boughton sold 6,236 shares of Hims & Hers Health stock. The shares were sold at an average price of $27.86, for a total transaction of $173,734.96.
• On Wednesday, September 2nd, Soleil Boughton sold 3,458 shares of Hims & Hers Health stock. The stock was sold at an average price of $28.33, for a total transaction of $97,965.14.
• On Wednesday, August 19th, Soleil Boughton sold 25,111 shares of Hims & Hers Health stock. The shares were sold at an average price of $27.55, for a total value of $691,808.05.

Hims & Hers Health Stock Performance

Shares of HIMS traded down $0.34 during mid-day trading on Friday, hitting $28.96. The company's stock had a trading volume of 10,052,970 shares, compared to its average volume of 23,671,156. The stock's 50-day moving average is $29.27 and its two-hundred day moving average is $28.24. The firm has a market capitalization of $6.76 billion, a PE ratio of -45.97 and a beta of 2.44. The company has a debt-to-equity ratio of 4.21, a quick ratio of 0.87 and a current ratio of 0.93. Hims & Hers Health, Inc. has a one year low of $13.74 and a one year high of $65.30.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its earnings results on Monday, August 10th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.32). The company had revenue of $753.21 million for the quarter, compared to analyst estimates of $698.90 million. Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. Hims & Hers Health's revenue for the quarter was up 38.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.17 earnings per share. As a group, sell-side analysts anticipate that Hims & Hers Health, Inc. will post -0.16 EPS for the current year.

Institutional Investors Weigh In On Hims & Hers Health

A number of hedge funds and other institutional investors have recently bought and sold shares of HIMS. QRG Capital Management Inc. bought a new position in Hims & Hers Health in the 2nd quarter valued at $248,000. Envestnet Portfolio Solutions Inc. lifted its position in Hims & Hers Health by 46.9% during the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 32,469 shares of the company's stock worth $1,126,000 after buying an additional 10,366 shares in the last quarter. Bienville Capital Management LLC bought a new stake in Hims & Hers Health during the 2nd quarter worth about $27,242,000. Engineers Gate Manager LP acquired a new stake in Hims & Hers Health in the 2nd quarter valued at about $232,000. Finally, Integrated Wealth Concepts LLC bought a new position in shares of Hims & Hers Health in the second quarter worth about $147,000. 63.52% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

HIMS has been the topic of several analyst reports. Zacks Research raised shares of Hims & Hers Health from a "strong sell" rating to a "hold" rating in a report on Monday, July 13th. Wall Street Zen raised shares of Hims & Hers Health from a "sell" rating to a "hold" rating in a research note on Saturday, August 15th. Deutsche Bank Aktiengesellschaft raised their price target on shares of Hims & Hers Health from $25.00 to $26.00 and gave the stock a "hold" rating in a research note on Tuesday, August 11th. Morgan Stanley lifted their price objective on Hims & Hers Health from $21.00 to $28.00 and gave the company an "equal weight" rating in a report on Tuesday, August 11th. Finally, TD Cowen increased their target price on Hims & Hers Health from $25.00 to $30.00 and gave the stock a "hold" rating in a report on Tuesday, August 11th. Three analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $32.43.

Key Headlines Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Hims & Hers and Hims Australia appointed chief medical officers in the United Kingdom and Australia, strengthening local clinical leadership as the company expands internationally. Hims & Hers Names Chief Medical Officers in the UK and Australia
• Neutral Sentiment: Multiple law firms, including Rosen, Kaplan Fox, SBS and Robbins Geller, reminded investors that purchasers of HIMS securities between August 4, 2025, and July 29, 2026, may seek appointment as lead plaintiff by November 2, 2026. These announcements are largely procedural and do not represent new claims by themselves. Rosen Securities Class Action Deadline Notice
• Negative Sentiment: Hims & Hers is the subject of a securities class action alleging that the company and certain executives made material misstatements or omissions, including regarding allegedly deceptive and unlawful privacy practices. The case reportedly follows an FTC complaint alleging serious business misconduct. The allegations have not been proven, but the litigation could create legal costs, potential damages and additional regulatory or reputational pressure. Hims & Hers Securities Class Action Following FTC Complaint
• Negative Sentiment: Recent reports noted that HIMS declined during a session in which the overall market rose, suggesting investor sentiment remains pressured by the FTC-related controversy and lawsuit headlines. Continued coverage from numerous plaintiff firms may keep volatility elevated while investors await developments in the case. HIMS Stock Slides as Market Rises

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a direct-to-consumer telehealth company that provides access to personalized healthcare through its online platforms, Hims and Hers. The company connects consumers with licensed healthcare professionals for virtual consultations, treatment plans and prescription medications where appropriate.

Its services address a range of common health and wellness needs, including sexual health, hair loss, skincare, mental health, weight management and primary care. Hims & Hers offers branded and generic treatments, over-the-counter products, supplements and personal-care products, with services designed for both men and women.

The company was founded in 2016, launched the Hims brand in 2017 and introduced the Hers brand in 2018.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.